Skip to main content

letter

. 2013 Apr 3;33(3):164. [Article in Spanish] doi: 10.1016/S0212-6567(04)79381-6

Rinorrea secundaria a espironolactona

L Ayerbe García-Monzón ^a, S Herrero Hernández ^b, E González López ^a, M Alcaraz Borrajo ^b

PMCID: PMC7677952 PMID: 14987504

The content is available as a PDF (167.2 KB).

References

1.Edwards I.R. Adverse drug reactions: definition, diagnosis and management. Lancet. 2000;356:1255–1259. doi: 10.1016/S0140-6736(00)02799-9. [DOI] [PubMed] [Google Scholar]
2.Dykewicz M.S., Fineman S. Executive summary of Joint Task Force Practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998;81:463–518. doi: 10.1016/S1081-1206(10)63152-3. [DOI] [PubMed] [Google Scholar]
3.McEvoy E.G., McEvoy E.G., editors. Drug information. American Hospital Formulary Service; Bethesda: 1999. Enalaprilat; pp. p.1420–p.1431. [Google Scholar]
4.Parfitt K. Pharmaceutical Press,; London: 1999. (Martindale. The complete drug reference. 32nd ed). [Google Scholar]

ACTIONS

RESOURCES